New hope for brain cancer: targeted pill plus chemo shows promise in early trial
NCT ID NCT07405255
First seen Feb 13, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests whether adding the targeted drug zanubrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with central nervous system lymphoma. About 19 participants will receive the combination, and those who respond well will continue zanubrutinib for 2 years to keep the cancer under control. The main goal is to see how many achieve complete remission after 6 treatment cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Conditions
Explore the condition pages connected to this study.